Your session is about to expire
← Back to Search
Gemcitabine + Docetaxel for Bladder Cancer (GEMDOCE Trial)
GEMDOCE Trial Summary
This trial is testing a new combination therapy for bladder cancer that has not yet been proven safe or effective. If the new therapy is found to be both safe and effective, it could become the new standard of care.
GEMDOCE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGEMDOCE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 256 Patients • NCT01005680GEMDOCE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have another cancer with a life expectancy of less than 12 months.I received cancer treatment less than 4 weeks ago or am still experiencing side effects.I had radiotherapy less than 4 weeks ago or still have side effects.I am willing and able to follow the study's requirements.I am post-menopausal or not pregnant.I am able to care for myself and perform daily activities.My bladder cancer is advanced and cannot be surgically removed.I have used gemcitabine or docetaxel for cancer other than bladder cancer.My bladder cancer is confirmed and not yet invasive.I am 18 years old or older.I have cancer in my upper urinary tract.
- Group 1: Intravesical Gemcitabine/Docetaxel
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we currently looking for new participants in this experiment?
"According to the most recent update on clinicaltrials.gov, this trial is no longer looking for patients. The study was first posted on 7/29/2020 but has not been updated since 8/18/2022. Although this particular trial has completed recruitment, there are 3623 other trials that are still enrolling patients."
Is Gemcitabine a drug with few adverse effects?
"While there is some evidence of Gemcitabine's safety, it did not receive a score higher than 2 because this is only a Phase 2 trial."
How many patients are enrolled in this clinical trial?
"Currently, this clinical trial is not accepting new patients. The original posting was on 7/29/2020 with the most recent update being made on 8/18/2022. If you are looking for other trials, there are 2865 active studies searching for patients with carcinoma and 758 trials actively enrolling patients that focus on Gemcitabine."
What conditions does Gemcitabine typically alleviate?
"Gemcitabine can be used to treat neoplasm metastasis, metastatic bladder cancer, and patients with advance directives."
What is the research history of Gemcitabine?
"There are 758 ongoing studies and 255 in Phase 3 that involve Gemcitabine. The research is being conducted all over the world with 42911 different trial locations, although a significant portion of the work is happening in Shanghai, China."
Share this study with friends
Copy Link
Messenger